UPM Pharmaceuticals will expand its existing manufacturing capacity with an OEB 4 processing room, a low humidity processing suite, and a dedicated Xcelodose production facility. The overall expansion will add 50% more manufacturing space for current production.

UPM’s president, James Gregory, said, “To meet our client’s growing needs, UPM is making a major capital commitment to enhance client services. In response to an increasing number of requests for production of compounds with more stringent environmental safety requirements, UPM is building a unique suite for handling of manufacturing processes associated with OEB 4 compounds. We are also building a dedicated suite for handling and production of low humidity compounds. Finally, UPM will be developing a unique segregated four-room suite to handle Xcelodose processing and encapsulation activities associated with the 600 and 600S equipment systems. We intend to provide these services under the strictest handling conditions up to and including OEB 4 compounds. This expansion will allow us to keep pace with our clients’ needs and continue our commitment to speed and quality in the services we provide.”